Compare ServiceNow Inc (NOW) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ServiceNow Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? ServiceNow Inc trades at $139.39 (market cap $143.30B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: ServiceNow Inc is far larger — about 29.4× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, ServiceNow Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ServiceNow Inc for 54 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| NOW | TVTX | |
|---|---|---|
Market Cap | $143.30B | $4.88B |
Volume | 13,207,010 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $189.26 | $67.52 |
52-Week Low | $83.00 | $26.79 |
Typical Hold Time | 54 Days | 0 Days |
Enterprise Value | $147.09B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ServiceNow (NOW) trades at $138.61, down 1.22% on the day, amid a bullish technical setup with strong analyst support. The stock shows robust fundamentals with revenue growth from $7.2B in 2022 to $13.3B in 2025, a high gross margin of 74.77%, and consistent earnings beats. Recent news highlights AI-driven momentum, with AI annual contract value surpassing $1B in Q2 2026, fueling positive sentiment despite premium valuations.
The outlook remains positive given AI adoption and earnings strength, but risks include stiff competition and high P/E of 86.63. With 87% of analysts rating it Buy and a consensus target of $150.74, the stock offers upside, though investors should weigh valuation concerns against growth prospects.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
